Table 3 Similar data from some of the published primary glomerulonephritis studies generated from international data
Country | All PGD Patients(%) | Patients with nephrotic syndrome | Biopsy indication (%) | |||||
|---|---|---|---|---|---|---|---|---|
1st | 2nd | 3rd | 1st | 2nd | 3rd | Nephrotic syndrome | AUA | |
Turkey (TSN-GOLD 2014) [5] | MN (28.8%) | FSGS (19.3%) | IgAN (17.2%) | MN (43.2%) | FSGS (19.7%) | MCD (10.3%) | 57.8 | 10.8 |
Turkey (TSN-GOLD 2019)a | IgAN (25.7%) | MN (25.6%) | FSGS (21.9%) | MN (39.8%) | FSGS (25.2%) | MCD (11.0%) | 52 | 18 |
France [23]b | IgAN (29.7%) | MN (19.0%) | CGN (16.8%) | – | – | – |  |  |
Italy [24] | IgAN (43.5%) | MN (23.4%) | FSGS (13.1%) | MN (44.1%) | FSGS (16.9%) | MCD (16.7%) | 45 | 51 |
Spain [25]c | – | – | – | MN | MCD | FSGS | 35 | 25 |
England [26] | IgAN (38.8%) | MN (29.4%) | MCD (9.8%) | – | – | – |  |  |
Czech Republic [27]c | IgAN (34.5%) | MCD (12.5%) | Mes.PGN(%11.3) | IgAN** | MN | FSGS | 42 | 37 |
Lithuania [28] | IgAN(34%) | FSGS (13.2%) | MPGN (12.5%) | – | – | – |  |  |
Japan [29] | IgAN (~  50%) | – | – | MCD (40%) | MN (35.6%) | FSGS (13%) | 16.5 | 48d |
South Korea [30] | IgAN (38.2%) | MCD | MN | MCD (38.5%) | MN (25.7%) | IgAN (11.1%) | Â | Â |
China [31] | IgAN (45.2%) | Mes. PGD (25.6%) | MN (9.9%) | – | – | – |  |  |
Brazil £ [32] | FSGS (29.7%) | MN (20.7%) | IgAN (17.8%) | – | – | – | 41.5 | 27.2 |
FSGS | IgAN | MN | FSGS | MN | MCD | Â | Â | |
Taiwan [34] | IgAN (26%) | FSGS (21.6%) | MN (20.6%) | MN (28.8%) | MCD (28.2%) | FSGS (24.8%) | Â | Â |
Colombia [11]f | IgAN (22.6%) | FSGS (20.1%) | MN (14.9%) | Â | Â | Â | Â | Â |
Poland [12] | IgAN (51.2%) | MPGN (19.3) | MN (11.2%) | MN | FSGS | IgAN | Â | Â |